BTG plc (LON:BTG) had its price target increased by stock analysts at JPMorgan Chase & Co. from GBX 790 ($10.31) to GBX 830 ($10.83) in a research report issued to clients and investors on Friday. The firm currently has a “neutral” rating on the stock. JPMorgan Chase & Co.’s price objective suggests a potential upside of 21.35% from the stock’s previous close.
BTG has been the subject of a number of other reports. Stifel Nicolaus cut BTG plc to a “hold” rating in a research note on Thursday, July 14th. Numis Securities Ltd reiterated a “hold” rating and issued a GBX 737 ($9.62) target price on shares of BTG plc in a report on Thursday, July 14th. Jefferies Group lifted their target price on BTG plc from GBX 840 ($10.96) to GBX 860 ($11.23) and gave the company a “buy” rating in a report on Wednesday, June 29th. Finally, Deutsche Bank AG reiterated a “buy” rating and issued a GBX 740 ($9.66) target price on shares of BTG plc in a report on Wednesday, June 15th. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of GBX 799.57 ($10.44).
BTG plc (LON:BTG) opened at 684.00 on Friday. The firm’s market capitalization is GBX 2.62 billion. BTG plc has a one year low of GBX 504.00 and a one year high of GBX 739.50. The stock has a 50 day moving average price of GBX 627.97 and a 200-day moving average price of GBX 640.80.
In other BTG plc news, insider Soderstrom,Rolf sold 74,327 shares of BTG plc stock in a transaction dated Thursday, July 21st. The stock was sold at an average price of GBX 676 ($8.82), for a total transaction of £502,450.52 ($655,855.01).
About BTG plc
BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.
Receive News & Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related companies with MarketBeat.com's FREE daily email newsletter.